Watch now for an expert panel discussion surrounding the ITIF report examining why the United States lost its lead in other advanced technology industries, and how policymakers can avoid repeating the same mistakes in the biopharmaceutical sector.

Tune in for an expert panel discussion examining where Japan faltered in this sector, what it must do to restore its life-sciences innovation leadership and competitiveness, why that would be in the best interests of both Japan and the United States—and what America must do to avoid following in Japan’s footsteps.

Watch the release event of a new report that examines the dynamics that underpin the economics of biopharmaceutical innovation and how to maintain a supportive environment that keeps the United States in the lead of life-sciences innovation.

ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.

ITIF hosted an expert panel discussion about the report and the vital role IP has played throughout the pandemic.

TauRx is revolutionizing Alzheimer's treatment with a novel drug that targets toxic brain proteins, offering fresh hope in the fight against this devastating disease.

InCurA is revolutionizing MENA's medical landscape with AI-optimized, locally produced hemostatic solutions like CurASeal, bridging the gap between innovation and accessibility while reducing reliance on global imports.

China used to be considered a laggard in biotech. But with a comprehensive national strategy and extensive resources now supporting the industry, it is becoming more innovative. In fact, several indicators suggest it is narrowing the innovation gap with global leaders in the West.

Mexico's newly elected president, Claudia Sheinbaum, can reverse President Andrés Manuel López Obrador's anti-innovation policies toward genetically modified maize, and improve the lives of small farmers across Mexico.

By improving privacy protection and facilitating secure collaborative research, privacy-enhancing technology could complement data-sharing policies and enable analysis of sensitive medical data and support biomedical innovation.

America’s innovation system is fragile, and its leadership in advanced technology industries is never guaranteed or assured. The United States has taken—only to sacrifice—its lead in a wide-range of advanced technology industries, often in part because of significant policy lapses. It’s no time for additional unforced errors.

The United States should not endorse an IPR waiver in the WHO Pandemic Preparedness Agreement. It would not increase the number of vaccines or therapeutics, or the global supply that might be needed to address a future global pandemic.